Lucid Diagnostics Inc.
Lucid Diagnostics Inc. (LUCD) Financial Performance & Income Statement Overview
Review Lucid Diagnostics Inc. (LUCD) income statement, balance sheet, and cash flow reports with annual and quarterly breakdowns.
Lucid Diagnostics Inc. (LUCD) Income Statement & Financial Overview
Analyze Lucid Diagnostics Inc.’s LUCD earnings with segmented quarterly and yearly financial statement figures.
| Metric | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 |
|---|---|---|---|---|
| Revenue | $1.20M | $1.17M | $976000.00 | $1.001M |
| Cost of Revenue | $2.15M | $1.68M | $1.84M | $2.16M |
| Gross Profit | -$948000.00 | -$512000.00 | -$867000.00 | -$1.16M |
| Gross Profit Ratio | -$0.79 | -$0.44 | -$0.89 | -$1.15 |
| R&D Expenses | $1.45M | $1.67M | $1.37M | $1.50M |
| SG&A Expenses | $9.87M | $9.30M | $9.08M | $8.13M |
| Operating Expenses | $11.43M | $10.97M | $10.32M | $9.64M |
| Total Costs & Expenses | $13.57M | $12.87M | $12.17M | $11.79M |
| Interest Income | $66000.00 | $81000.00 | $107000.00 | $68000.00 |
| Interest Expense | $7000.00 | $1000.00 | $6000.00 | $12000.00 |
| Depreciation & Amortization | $222000.00 | $215000.00 | $229000.00 | $501000.00 |
| EBITDA | -$11.31M | -$12.15M | -$10.77M | -$10.10M |
| EBITDA Ratio | -$9.45 | -$10.37 | -$11.03 | -$10.09 |
| Operating Income | -$12.38M | -$11.69M | -$11.19M | -$10.79M |
| Operating Income Ratio | -$10.34 | -$9.98 | -$11.47 | -$10.78 |
| Other Income/Expenses (Net) | $834000.00 | -$677000.00 | $187000.00 | $180000.00 |
| Income Before Tax | -$11.54M | -$12.37M | -$11.005M | -$10.61M |
| Income Before Tax Ratio | -$9.64 | -$10.56 | -$11.28 | -$10.60 |
| Income Tax Expense | $0.00 | $0.00 | $0.00 | $7.50B |
| Net Income | -$11.54M | -$12.37M | -$11.005M | -$10.61M |
| Net Income Ratio | -$9.64 | -$10.56 | -$11.28 | -$10.60 |
| EPS | -$0.23 | -$0.25 | -$0.23 | -$0.24 |
| Diluted EPS | -$0.23 | -$0.25 | -$0.23 | -$0.24 |
| Weighted Avg Shares Outstanding | $58.38M | $50.37M | $48.21M | $45.01M |
| Weighted Avg Shares Outstanding (Diluted) | $58.38M | $50.37M | $48.21M | $45.01M |
Over the past four quarters, Lucid Diagnostics Inc. demonstrated steady revenue growth, increasing from $1.001M in Q1 2024 to $1.20M in Q4 2024. Operating income reached -$12.38M in Q4 2024, maintaining a consistent -1034% margin over recent quarters. Despite fluctuations in R&D and SG&A expenses, EBITDA remained robust at -$11.31M, reflecting operational efficiency. Net income rose to -$11.54M, with EPS at -$0.23. Disciplined expense management helped sustain profitability, highlighting solid overall financial performance.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan